atai Life Sciences buying at IntelGenx Technologies (IGX)

atai Life Sciences buying at IntelGenx Technologies (T:IGX)

atai Life Sciences AG, a 10% Holder, acquired 37,300,000 Common Shares on a direct ownership basis at a price of US$0.331 through a private transaction on May 14th, 2021. The insider also acquired 22,380,000 Warrants with at an exercise price of US$0.350 until May 14, 2024. This represents a $14,950,135 investment into the company's shares and an account share holdings change of greater than 100%.

IntelGenx Technologies is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

IntelGenx Technologies Corp is a Canada-based drug delivery company focused on the development of oral immediate-release and controlled-release products and on developing pharmaceutical products based on its drug delivery technologies. Its product development efforts are based upon over three delivery platform technologies, such as VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology, and AdVersa, a mucoadhesive tablet technology. The VersaFilm technology consists of a thin (25 to 35 micron) polymeric film consisting of the United States Pharmacopeia (USP) components for use in food, pharmaceutical and cosmetic products. Its Multilayer Tablet platform technology allows for the development of oral controlled-release products. Its product portfolio includes INT0001/2004, INT0004/2006, INT0007/2006, INT0008/2007, INT0010/2006, INT0027/2011, INT0030/2011, INT0036/2013, INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015 and INT0043/2015.